SCHEMBL6893687

SCHEMBL6893687

O=C(CN1CCN(CC(=O)Nc2ccccc2)CCN(CC(=O)Nc2ccccc2)CC1)Nc1ccccc1

nearest known ligand 0.81

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.79
NPC1 O15118 2/20 0.78
KDM4E B2RXH2 1/20 0.78
LMNA P02545 1/20 0.78
SMN1; SMN2 Q16637 1/20 0.78
MEN1 O00255 2/20 0.77
KMT2A Q03164 2/20 0.77
TP53 P04637 1/20 0.76
RAB9A P51151 1/20 0.76
CHRNB2 P17787 1/20 0.72
CHRNB4 P30926 1/20 0.72
CHRNA3 P32297 1/20 0.72
CHRNA4 P43681 1/20 0.72
ME2 P23368 1/20 0.72
ME1 P48163 1/20 0.72
ME3 Q16798 1/20 0.72
REV1 Q9UBZ9 1/20 0.70
KCNA5 P22460 1/20 0.70
THRB P10828 1/20 0.68
NPSR1 Q6W5P4 1/20 0.68

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14192211 0.95 ALDH1A1 (0.72) ALDH1A1NPC1KDM4ELMNASMN1; SMN2
SCHEMBL11147683 0.93 ALDH1A1 (0.90) ALDH1A1NPC1KDM4ELMNASMN1; SMN2
SCHEMBL17616061 0.92 ALDH1A1 (0.68) ALDH1A1NPC1KDM4ELMNASMN1; SMN2
SCHEMBL10474169 0.92 LMNA (0.77) ALDH1A1NPC1KDM4ELMNASMN1; SMN2
SCHEMBL6795359 0.91 ALDH1A1 (0.94) ALDH1A1NPC1KDM4ELMNASMN1; SMN2
SCHEMBL3839081 0.90 MEN1 (0.74) ALDH1A1NPC1KDM4ELMNASMN1; SMN2
SCHEMBL8009141 0.90 ALDH1A1 (0.69) ALDH1A1NPC1KDM4ELMNASMN1; SMN2
SCHEMBL8585760 0.89 NPC1 (0.67) ALDH1A1NPC1KDM4ELMNASMN1; SMN2
SCHEMBL5536418 0.89 ALDH1A1 (0.67) ALDH1A1NPC1KDM4ELMNASMN1; SMN2
SCHEMBL7511057 0.88 ALDH1A1 (0.68) ALDH1A1NPC1KDM4ELMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5874573-A Compounds with chelation affinity and selectivity for first transition series elements: use in medical therapy CONCAT, INC. (US) 1999-02-23 US claimed
US-20220031870-A1 METAL COMPLEXES AND FLUORINATION THEREOF UNIVERSITY OF SOUTHAMPTON (GB) 2022-02-03 US disclosed
US-20160082136-A1 METAL COMPLEXES AND FLUORINATION THEREOF UNIVERSITY OF SOUTHAMPTON (GB) 2016-03-24 US disclosed
EP-1382332-A1 Method for inhibiting bacterial or fungal growth using a polyamine derivative as complexing agent Chelator LLC (US) 2004-01-21 EP disclosed
US-6165996-A Compounds with chelation affinity selectivity for first transition series elements: use in medical therapy and diagnosis CONCAT, INC. (US) 2000-12-26 US disclosed
EP-0955044-A2 Method of inhibiting bacterial or fungal growth using a complexing agent CONCAT LTD. (US) 1999-11-10 EP disclosed
EP-0841951-A2 COMPOUNDS WITH CHELATION AFFINITY AND SELECTIVITY FOR FIRST TRANSITION SERIES ELEMENTS, AND THEIR USE IN MEDICAL THERAPY AND DIAGNOSIS CONCAT LTD. (US) 1998-05-20 EP disclosed
WO-1997001360-A2 COMPOUNDS WITH CHELATION AFFINITY AND SELECTIVITY FOR FIRST TRANSITION SERIES ELEMENTS AND THEIR USE IN MEDICAL THERAPY AND DIAGNOSIS CONCAT, LTD. (US) 1997-01-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220031870-A1 METAL COMPLEXES AND FLUORINATION THEREOF FOS, FGB, FOSB ALDH1A1 3176/4885NPC1 664/4885KDM4E 3099/4885
US-20160082136-A1 METAL COMPLEXES AND FLUORINATION THEREOF FOS, FGB, FOSB ALDH1A1 3309/4885NPC1 747/4885KDM4E 3216/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.